Cialis Soft

Cialis Soft is an innovative drug for eliminating problems with impaired potency. This drug can be taken once to improve potency before sexual contact or a course for the treatment of erectile problems. The drug is good because it can be used at any time of the day and is compatible with alcohol in small volumes. The effectiveness of Cialis Soft depends on the dosage and frequency of administration. Soft tablets has a sweet taste. The doctor can also prescribe a double dosage for severe problems with potency and erection.

Indications for use

Erectile dysfunction.

Contraindications

  • Established hypersensitivity to tadalafil or to any substance that is part of the drug;
  • intake of medications containing any organic nitrates;
  • people under 18 years of age.

Take the drug with caution

Since there are no data on patients with severe hepatic impairment (according to the Child-Pugh Class C classification), better to prescribe Cialis with caution in the following cases:

alpha-blockers, such as doxazosin, since concomitant use can lead to symptomatic hypotension in some patients. In a clinical pharmacology study in 18 healthy volunteers taking a single dose of tadalafil, symptomatic hypotension was not found with the simultaneous administration of tamsulosin, an alpha [1A] -blocker.

Mode of administration and dosage

Cialis Soft dissolves under the tongue.The recommended maximum dose of Cialis is 20 mg. Cialis is taken before the planned sexual activity, regardless of food intake. The drug should be taken at least 16 minutes before the planned sexual intercourse. Patients can carry out intercourse at any time within 36 hours after taking the drug in order to establish the optimal response time to the drug. The maximum recommended frequency of admission is once a day.

Side effects

The most commonly reported side effects are headache and dyspepsia (11% and 7% of cases, respectively). Adverse events associated with taking tadalafil were usually mild or moderate in severity, transient, and decreased with continued use of the drug.

Other common side effects were back pain, myalgia, nasal congestion, and flushing. Rare side effects are edema of the eyelids, eye pain, conjunctival hyperemia and dizziness.

Very rare side effects: hypersensitivity reactions (including rashes, urticaria and facial edema, Stevens-Johnson syndrome and exfoliative dermatitis); hypotension (in patients who have already taken antihypertensive drugs); hypertension and syncope; abdominal pain and gastroesophageal reflux; hyperhidrosis (excessive sweating); priapism and delayed erection; blurry vision; non-arterial anterior ischemic neuropathy of the optic nerve; retinal vein occlusion; violation of visual fields.

Myocardial infarction, sudden cardiogenic death, stroke, chest pain, palpitations, and tachycardia have been observed in patients with previous cardiovascular risk factors. However, it is impossible to determine whether these events are directly related to these risk factors, tadalafil, sexual arousal, or a combination of these or other factors.

Overdose

With a single administration of tadalafil to healthy individuals at a dose of up to 500 mg and patients with erectile dysfunction (multiple times up to 100 mg per day), the undesirable effects were the same as when using lower doses. In case of overdose, it is necessary to carry out standard symptomatic treatment. With hemodialysis, tadalafil is practically not excreted.

Interactions

Tadalafil is mainly metabolized with the participation of the CYP3A4 enzyme. A selective inhibitor of CYP3A4, ketoconazole (400 mg per day), increases the exposure to a single dose of tadalafil (AUC) by 312% and Cmax by 22%, and ketoconazop (200 mg per day) increases the exposure to a single dose of tadalafil (AUC) by 107% and Cmax by 15% relative to AUC and Cmax values for tadalafil alone.

Ritonavir (200 mg twice daily), an inhibitor of CYP3A4, 2C9, 2C1E and 2D6, increases the exposure to a single dose of tadalafil (AUC) by 24% without changing Cmax. Despite the fact that specific interactions have not been studied, it can be assumed that other inhibitors of HIV protease, such as saquinavir, as well as inhibitors of CYPZA4, such as erythromycin and intraconazole, increase the activity of tadalafil.

A selective inducer of CYP3A4, rifampin (rifampicin, 600 mg per day), reduces the effect of a single dose of tadalafil (AUC) by 88% and Cmax by 46%, relative to AUC and Cmax values for tadalafil alone. It can be assumed that the simultaneous administration of other inducers of CYP3A4 should also reduce plasma tadalafil concentrations.

The simultaneous intake of an antacid (magnesium hydroxide/aluminum hydroxide) and tadalafil reduces the rate of tadalafil absorption without changing the area under the concentration time curve for tadalafil.

An increase in gastric pH as a result of taking the H2-antagonist nizatidine did not affect the pharmacokinetics of tadalafil.